Atherogenic mechanisms: enhancement of regression of atheromatous lesions by phthalazinol.
Atherosclerosis was produced in rabbits by feeding 1% cholesterol pellets for 15 weeks to 35 male rabbits divided into two equal groups--the placebo control and phthalazinol group--with a comparable serum cholesterol level. The phthalazinol group was given 20 mg/kg of the compound daily. 13 rabbits of both groups were on 15 weeks of the treatment and the remaining 22 rabbits were treated for 30 weeks. The treated group exhibited a statistically significant increased removal of cholesterol from atherosclerotic aortas and improvement in pathological changes. This enhancing effect was more marked in the animals treated for 30 weeks. Such evidence indicates that there are substances capable of enhancing the removal of cholesterol from atheromatous lesions. In light of the pharmacological properties of phthalazinol, the possible role of thromboxane A2 released from platelets adhered and aggregated on atheromatous plaques, in the progression of atherosclerosis is worthy of continued investigation.
D000818:Animals; D001158:Arteries / Q000473:pathology; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D004036:Diet, Atherogenic; D008297:Male; D010793:Phthalazines / Q000627:therapeutic use*; D010919:Placebos; D011724:Pyridazines / Q000627:therapeutic use*; D011817:Rabbits; D012075:Remission, Spontaneous
D010793:Phthalazines; D010919:Placebos; D011724:Pyridazines; D002784:Cholesterol